AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 11 - (NewsRx.com & NewsRx.net) -- by Lynn Yoffee, senior medical writer - A chemotherapy drug used to treat metastatic breast cancer significantly reduces the risk of recurrence and improves survival in women with early stage breast cancer, according to interim results of a large, international phase III study presented at the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Almost 3 years after treatment, the drug docetaxel (Taxotere), when combined with doxorubicin and cyclophosphamide, reduced the risk of breast cancer recurrence by 32%, compared with a standard chemotherapy (5-fluorouracil plus doxorubicin and cyclophosphamide). All women received chemotherapy after surgery to remove the primary breast tumor.
The docetaxel-based therapy (called TAC) showed the most benefit in women whose breast cancer had spread to 1-3 lymph nodes. For these women, TAC reduced the mortality rate by 54% and the risk of recurrence by 50%.
"While further follow up is necessary, these initial results merit consideration in choosing therapy for many women diagnosed with early breast ...
Source: HighBeam Research, Taxotere works against early breast cancer.(Brief Article)